Brokerages Set Merus (NASDAQ:MRUS) Price Target at $56.33

Merus (NASDAQ:MRUS) has received a consensus recommendation of “Buy” from the eleven brokerages that are currently covering the stock, MarketBeat.com reports. Eleven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $56.33.

Several research firms have recently commented on MRUS. HC Wainwright upped their target price on Merus from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. William Blair reaffirmed an “outperform” rating on shares of Merus in a report on Monday. Truist Financial initiated coverage on Merus in a research report on Thursday, March 28th. They set a “buy” rating and a $69.00 price objective on the stock. BMO Capital Markets boosted their target price on shares of Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Finally, Stifel Nicolaus raised their price target on shares of Merus from $40.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th.

Merus Price Performance

Shares of Merus stock opened at $41.97 on Monday. Merus has a 1 year low of $18.21 and a 1 year high of $52.03. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of -13.81 and a beta of 1.10. The business has a fifty day simple moving average of $45.03 and a two-hundred day simple moving average of $33.52.

Merus (NASDAQ:MRUS) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.38). Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. The company had revenue of $8.94 million for the quarter, compared to analyst estimates of $10.43 million. As a group, equities analysts anticipate that Merus will post -3.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Merus

Several hedge funds and other institutional investors have recently made changes to their positions in MRUS. AE Wealth Management LLC increased its stake in shares of Merus by 14.2% in the 3rd quarter. AE Wealth Management LLC now owns 22,500 shares of the biotechnology company’s stock valued at $531,000 after purchasing an additional 2,801 shares during the last quarter. Mach 1 Financial Group LLC raised its stake in Merus by 13.9% during the third quarter. Mach 1 Financial Group LLC now owns 22,435 shares of the biotechnology company’s stock worth $529,000 after acquiring an additional 2,736 shares in the last quarter. BluePath Capital Management LLC bought a new position in shares of Merus in the third quarter worth about $33,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Merus by 142.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 867 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in shares of Merus by 47.9% during the 3rd quarter. Teacher Retirement System of Texas now owns 12,084 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 3,916 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors and hedge funds.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.